key: cord-343739-t3z6ghyp
authors: Conforti, Claudio; Giuffrida, Roberta; Di Meo, Nicola; Zalaudek, Iris
title: Management of advanced melanoma in the COVID‐19 era
date: 2020-05-14
journal: Dermatol Ther
DOI: 10.1111/dth.13444
sha: 
doc_id: 343739
cord_uid: t3z6ghyp

nan

visits and surgery that cannot be postponed are carried out regularly.

For patients undergoing treatment with immunosuppressive or immunomodulating drugs for chronic dermatological diseases, such as psoriasis, several guidelines suggest to assess on a case-by-case basis the initiation of a new therapy with a biological drug as well as the possible suspension in case of positivity. 2 Apart from psoriasis, which can sometimes also be treated in an alternative way, we must focus our attention on the most fragile patients in dermatology, that is, oncologic patients suffering from advanced melanoma. In fact, we should remember that cancer-related treatments may cause immunosuppression, and the first available data suggest that patients with cancer have a risk of excess mortality due to SARS-CoV-2. 

Coronavirus disease 2019 (COVID-19): facts and controversies

COVID-19 and psoriasis: is it time to limit treatment with immunosuppressants? A call for action

Oncology practice during the COVID-19 pandemic

Infezione da Coronavirus: Vademecum per i pazienti affetti da psoriasi cutanea e/o artropatia psoriasica

AIOM, Rischio infettivo da Coronavirus Covid-19: indicazioni per l'oncologia

Cancer patient management during the covid-19 pandemic